戻る Agenda
Session 2: Physician’s Challenges – Treatment Pathways
Session Chair(s)
Sam Khalil
Worldwide Head of Medical Affairs, Immunology, Hepatology and Dermatology
Novartis, Switzerland
Speaker(s)
Biologic Medicines – The New Normal
Sam Khalil
Novartis, Switzerland
Worldwide Head of Medical Affairs, Immunology, Hepatology and Dermatology
Immunogenicity – The Wrong Elephant in the Room
Paul Chamberlain
NDA Advisory Board, United Kingdom
Biopharmaceuticals & Immunogenicity Expert
The NOR-SWITCH Study
Kristin Kaasen Jørgensen, MD, PHD
Akershus University Hospital, Norway
Gastroenterologist
ESNO Guideline: Switch Management Between Similar Biological Medicines
Hanneke Voorneveld
Maasstad Hospital, Netherlands
Nurse Practitioner Rheumatology